In a different study, it has been shown that targeting CD47 enhanced the effect of doxorubicin chemotherapy in vivo by reducing tumor growth and metastatic spread by activation of an antitumor innate immune response (Feliz‐Mosquea et al., 2018; Iribarren et al., 2019). This evidence concerns the gene CD47 and neoplasm.